Furthermore, we observed BORIS overexpression (calculated as >2-fold increase compared with the mean expression in healthy controls) in 26% of endometrial carcinomas and 62% of uterine sarcomas (Table 1). Here, CTCFL is linked to endometrial carcinoma.